NeuroPace, Inc. (NPCE)
NASDAQ: NPCE · Real-Time Price · USD
15.64
-0.20 (-1.26%)
At close: Jun 12, 2026, 4:00 PM EDT
15.61
-0.03 (-0.19%)
After-hours: Jun 12, 2026, 6:27 PM EDT
NeuroPace Revenue
NeuroPace had revenue of $22.07M in the quarter ending March 31, 2026, a decrease of -2.02%. This brings the company's revenue in the last twelve months to $99.53M, up 18.06% year-over-year. In the year 2025, NeuroPace had annual revenue of $99.99M with 25.13% growth.
Revenue (ttm)
$99.53M
Revenue Growth
+18.06%
P/S Ratio
5.36
Revenue / Employee
$452,409
Employees
220
Market Cap
533.23M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 99.99M | 20.08M | 25.13% |
| Dec 31, 2024 | 79.91M | 14.49M | 22.14% |
| Dec 31, 2023 | 65.42M | 19.90M | 43.72% |
| Dec 31, 2022 | 45.52M | 337.00K | 0.75% |
| Dec 31, 2021 | 45.18M | 4.05M | 9.83% |
| Dec 31, 2020 | 41.14M | 4.17M | 11.27% |
| Dec 31, 2019 | 36.97M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Varex Imaging | 857.50M |
| Tactile Systems Technology | 343.52M |
| OrthoPediatrics | 243.30M |
| Cerus | 216.56M |
| SI-BONE | 206.22M |
| Cytek Biosciences | 204.17M |
| Pacific Biosciences of California | 160.03M |
| Beta Bionics | 110.24M |
NPCE News
- 8 days ago - NeuroPace Transcript: AGM 2026 - Transcripts
- 15 days ago - NeuroPace announces FDA approval of ECoG Assistant - TheFly
- 15 days ago - NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting - Business Wire
- 15 days ago - NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care - Business Wire
- 4 weeks ago - NeuroPace price target raised to $20 from $19 at H.C. Wainwright - TheFly
- 4 weeks ago - NeuroPace reports Q1 EPS (20c), consensus (23c) - TheFly
- 4 weeks ago - NeuroPace raises FY26 revenue view to $99M-$101M from $98M-$100M - TheFly
- 4 weeks ago - NeuroPace Earnings Call Transcript: Q1 2026 - Transcripts